Revvity(US:RVTY)2026-02-02 14:02Financial Data and Key Metrics Changes - In Q4 2025, the company generated revenue of $772 million, resulting in 4% organic growth, with a full-year revenue of $2.86 billion, reflecting 3% organic growth [22][24] - Adjusted EPS for Q4 was $1.70, exceeding the high end of expectations, while full-year adjusted EPS was $5.06, representing 3% growth year-over-year [10][24] - Adjusted operating margins for Q4 were 29.7%, down 60 basis points year-over-year, and for the full year, they were 27.1%, down 120 basis points year-over-year [23][24] Business Line Data and Key Metrics Changes - The diagnostics segment saw revenue of $390 million in Q4, up 10% reported and 7% organic, while the life sciences segment generated $382 million, flat on an organic basis [26][28] - For the full year, diagnostics grew 4% organically, while life sciences grew 2% organically [26][27] - The Signals software business was flat year-over-year organically in Q4 but grew in the high teens organically for the full year [27] Market Data and Key Metrics Changes - Geographically, the company experienced flat performance in both the Americas and APAC, with double-digit growth in Europe [26] - For the full year, the Americas grew low single digits, Europe grew high single digits, and APAC declined in the low single digits [26] Company Strategy and Development Direction - The company plans to continue capital deployment through share repurchases and acquisitions, having repurchased over $800 million worth of shares in 2025 [10][11] - The acquisition of ACD/Labs is expected to contribute over $20 million in revenue in 2026, adding approximately 75 basis points to overall revenue growth [12][13] - The introduction of the AI models-as-a-service platform, Signals Xynthetica, is aimed at enhancing drug development processes [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding the recovery of end markets, reiterating a 2%-3% organic growth outlook for 2026 [12][31] - The company noted potential upside from improved customer sentiment in pharma and biotech, as well as ongoing cost efficiency initiatives [20][22] - Management highlighted the importance of maintaining a disciplined approach to capital deployment while navigating a fluid market environment [11][20] Other Important Information - The company generated free cash flow of $162 million in Q4, resulting in 84% conversion of adjusted net income, with a full-year free cash flow of $515 million [25] - The net debt to adjusted EBITDA leverage ratio was 2.7x, with 100% of debt being fixed rate [25] Q&A Session Summary Question: Can you provide more color on the 2%-3% organic growth framework and potential upside? - Management acknowledged positive signs in end markets since September and identified multiple paths for potential upside in both revenue and EPS [39][40] Question: What is the outlook for life sciences versus diagnostics relative to the 2%-3% growth? - Management indicated that life sciences is expected to grow at low single digits, while diagnostics is also expected to grow at low single digits, with specific growth rates for sub-segments [55] Question: How is the company approaching M&A opportunities? - Management stated that any potential M&A must provide a strong strategic addition and that they have not yet identified compelling targets [58] Question: Can you elaborate on the performance within pharma biotech and order trends? - Management noted cautious optimism and consistency in order trends, with no budget flush observed but improved clarity in the policy environment [60][61] Question: What are the expectations for the diagnostics business going into 2026? - Management expressed that diagnostics could provide upside, particularly in newborn screening and immunodiagnostics, despite taking a more prudent approach to assumptions [63][64]